Article

Phase III trial to compare wet AMD drugs

Regeneron Pharmaceuticals Inc. and Bayer HealthCare have initiated a phase III study of a fusion protein anti-vascular endothelial growth factor (VEGF Trap-Eye) in the neovascular form of age-related macular degeneration (wet AMD).

Tarrytown, NY-Regeneron Pharmaceuticals Inc. and Bayer HealthCare have initiated a phase III study of a fusion protein anti-vascular endothelial growth factor (VEGF Trap-Eye) in the neovascular form of age-related macular degeneration (wet AMD).

The study will compare the agent, administered at 4-and 8-week intervals, and ranibizumab (Lucentis, Genentech), administered at 4-week intervals. About 1,200 patients throughout the United States and Canada will be enrolled in the randomized, double-masked study. Patients will be given 0.5-mg and 2-mg doses at 4-week intervals, and 2 mg at 8-week intervals, compared with 0.5 mg of ranibizumab every 4 weeks.

The study hopes patients' vision will improve or lose fewer than 3 lines on an Early Treatment Diabetic Retinopathy Study chart at the end of 1 year.

In an analysis of interim data from the ongoing phase II trial, in which patients were treated with the agent monthly or quarterly, patients demonstrated a statistically significant reduction in retinal thickness and improvement in visual acuity after 12 weeks, compared with baseline.

Regeneron and Bayer are collaborating on the drug development. Bayer will market the drug outside the United States, while Regeneron maintains rights in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.